Roche says U.S. FDA issues Emergency Use Authorization for Zika test
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Roche tablets are seen positioned in front of a displayed Roche logo in this photo illustration shot January 22, 2016. REUTERS/Dado Ruvic/Illustration/File Photo
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
ZURICH (Reuters) - Swiss drugmaker Roche (NYSE: ROG) said on Monday the U.S. Food and Drug Administration (FDA) had issued an Emergency Use Authorization (EUA) for its test for the Zika virus.
"The LightMix Zika test is an easy-to-use molecular diagnostic test that enables healthcare professionals to quickly detect the virus," said Uwe Oberlaender, the head of molecular diagnostics at Basel-based Roche.
The virus has been associated with microcephaly, a birth defect characterized by an unusually small head and potential developmental problems.
(Reporting by Joshua Franklin; Editing by Subhranshu Sahu)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Roche expands distribution alliance with the life science business of Merck KGaA, Darmstadt, Germany to include Kapa Biosystems qPCR and endpoint PCR Portfolios
- U.S. justices to weigh $4 million damages in California police shooting
- Additional charge for Michigan man in counterterrorism probe
Create E-mail Alert Related CategoriesReuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!